Bicara Therapeutics Inc (BCAX)
R&D Expense Growth
96.63%
Fiscal year · Period ending:
BCAX R&D Expense Growth
Latest reported96.63%period ending
Latest reported96.63%period ending
BCAX FY R&D Growth (YoY) (0.00% → 96.63%)
Latest values, visible window
High-resolution chart · PNG
BCAX r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 96.6331% | |
| 107.7898% | |
| -2.2196% | |
| 0% |